StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Bio-Path Stock Up 3.3 %

Shares of BPTH stock opened at $0.87 on Tuesday. The stock has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.11. Bio-Path has a 1-year low of $0.59 and a 1-year high of $9.99.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.